MXPA04002006A - Analogos de prostagladina como abridor del canal de cloruro. - Google Patents

Analogos de prostagladina como abridor del canal de cloruro.

Info

Publication number
MXPA04002006A
MXPA04002006A MXPA04002006A MXPA04002006A MXPA04002006A MX PA04002006 A MXPA04002006 A MX PA04002006A MX PA04002006 A MXPA04002006 A MX PA04002006A MX PA04002006 A MXPA04002006 A MX PA04002006A MX PA04002006 A MXPA04002006 A MX PA04002006A
Authority
MX
Mexico
Prior art keywords
channel opener
chloride channel
prostaglandin analogs
chloride
prostaglandin compound
Prior art date
Application number
MXPA04002006A
Other languages
English (en)
Inventor
Ueno Ryuji
Original Assignee
Sucampo Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26980134&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MXPA04002006(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sucampo Ag filed Critical Sucampo Ag
Publication of MXPA04002006A publication Critical patent/MXPA04002006A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Se describe el uso novedoso de un compuesto de prostaglandina como un abridor del canal de cloruro; de acuerdo con la presente invencion, los canales de cloruro en un sujeto mamifero pueden abrirse por un compuesto de prostaglandina para facilitar el transporte del ion cloruro.
MXPA04002006A 2001-08-31 2002-08-29 Analogos de prostagladina como abridor del canal de cloruro. MXPA04002006A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31591701P 2001-08-31 2001-08-31
US37210402P 2002-04-15 2002-04-15
PCT/JP2002/008705 WO2003030912A1 (en) 2001-08-31 2002-08-29 Prostaglandin analogs as chloride channel opener

Publications (1)

Publication Number Publication Date
MXPA04002006A true MXPA04002006A (es) 2004-06-07

Family

ID=26980134

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04002006A MXPA04002006A (es) 2001-08-31 2002-08-29 Analogos de prostagladina como abridor del canal de cloruro.

Country Status (11)

Country Link
US (2) US7064148B2 (es)
EP (1) EP1420794B1 (es)
JP (2) JP4786866B2 (es)
AR (1) AR036391A1 (es)
AU (1) AU2002330747B2 (es)
BR (1) BR0212233A (es)
CA (1) CA2458471C (es)
MX (1) MXPA04002006A (es)
NZ (1) NZ531503A (es)
TW (1) TWI298256B (es)
WO (1) WO2003030912A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4597481B2 (ja) * 2001-05-18 2010-12-15 スキャンポ・アーゲー 下剤組成物
TWI331920B (en) 2001-11-14 2010-10-21 Sucampo Ag Unit dosage form for relieving or treating constipation in human patients
TWI263505B (en) * 2001-11-19 2006-10-11 Sucampo Ag Pharmaceutical composition comprising a C1C-2 channel opener
PT1562604E (pt) * 2002-10-23 2012-04-09 Sucampo Ag Compostos de prostaglandina para o tratamento de obesidade
BRPI0317740B8 (pt) * 2002-12-27 2021-05-25 Sucampo Ag uso do composto 13,14-diidro-15-ceto-16,16-diflúorprostaglandina e1
WO2005002588A1 (en) * 2003-07-03 2005-01-13 Sucampo Ag Enteric coated composition comprising prostaglandin analogs as chloride channel opener
TWI495471B (zh) * 2003-08-12 2015-08-11 R Tech Ueno Ltd 促進毛髮生長之組成物及方法
TWI387454B (zh) * 2004-09-02 2013-03-01 Sucampo Ag 治療胃腸道疾病之方法及組成物
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
CN101171010B (zh) * 2005-03-07 2014-09-17 芝加哥大学 阿片样物质拮抗剂用于减少内皮细胞增殖和迁移的用途
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US20060281818A1 (en) 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders
WO2006109881A1 (en) * 2005-04-12 2006-10-19 Sucampo Ag Combined use of prostaglandin compound and proton pump inhibitor for the treatment of gastrointestinal disorders
JP5377970B2 (ja) * 2006-02-28 2013-12-25 スキャンポ・アーゲー 慢性閉塞性肺疾患を処置するための方法および組成物
EP2059247A1 (en) * 2006-09-06 2009-05-20 Sucampo AG Method and composition for promoting gastrointestinal bicarbonate secretion
EP2114411A2 (en) * 2007-02-27 2009-11-11 Sucampo AG Composition and method for protecting mitochondria
US20090012165A1 (en) 2007-07-03 2009-01-08 Sucampo Ag Pharmaceutical combination of nsaid and prostaglandin compound
US20090030072A1 (en) * 2007-07-03 2009-01-29 Sucampo Ag Pharmaceutical combination of opioid and prostaglandin compound
CA2702094C (en) 2007-10-10 2018-05-01 Parion Sciences, Inc. Delivering osmolytes by nasal cannula
CN101318948B (zh) * 2008-04-01 2011-04-27 上海天伟生物制药有限公司 鲁比前列酮晶体、其制备方法及用途
US20110034424A1 (en) * 2009-06-30 2011-02-10 Sucampo Ag Method for the long term nsaid use
CN102548559B (zh) * 2009-08-07 2013-12-25 塞法姆公司 用于治疗囊性纤维化的组合物
US20110071163A1 (en) * 2009-09-18 2011-03-24 Adolor Corporation Use of an opioid receptor antagonist for the treatment or prevention of gastrointestinal tract disorders
HUE031652T2 (en) * 2011-02-07 2017-07-28 Scipharm Sarl New composition for treating cystic fibrosis
US8778383B2 (en) 2011-06-07 2014-07-15 Parion Sciences, Inc. Methods of treatment
US8945605B2 (en) 2011-06-07 2015-02-03 Parion Sciences, Inc. Aerosol delivery systems, compositions and methods
WO2014085655A1 (en) * 2012-11-29 2014-06-05 Indiana University Research And Technology Corporation Dielectric electrolyte measurement device
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space
US20150057351A1 (en) * 2013-08-22 2015-02-26 Sucampo Ag Method for treating neuropathic pain
EP3053575B1 (en) * 2013-10-04 2020-09-02 Tohoku University Agent for preventing or ameliorating renal dysfunction
US11534404B2 (en) 2016-10-06 2022-12-27 Sucampo Ag Multilayer beads for pharmaceutical use
CN110267670B (zh) 2016-10-20 2023-08-15 表飞鸣制药株式会社 对肠道的离子跨细胞转运体的作用剂、氯离子通道活化剂、肾脏疾病的预防或治疗剂或者排便促进剂
US10457623B1 (en) * 2018-07-13 2019-10-29 Chirogate International Inc. Process for the preparation of Lubiprostone and intermediates thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE43462B1 (en) * 1975-06-23 1981-03-11 Pfizer Substituted tetranorprostaglandins
US4091207A (en) * 1976-04-22 1978-05-23 Pfizer Inc. Prostaglandin intermediate including oxathio heterocyclic ring
IT1098350B (it) * 1977-07-28 1985-09-07 Upjohn Co Derivati prostaglandinici
JPS6033429B2 (ja) * 1980-04-28 1985-08-02 小野薬品工業株式会社 プロスタグランジン類似化合物
US5166174A (en) 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
CA1322749C (en) 1987-01-28 1993-10-05 Ryuzo Ueno Prostaglandins of the d series, and tranquilizers and soporifics containing the same
US5221763A (en) 1987-04-30 1993-06-22 R-Tech Ueno, Ltd. Prostaglandins of the F series
JPH0681728B2 (ja) * 1987-10-02 1994-10-19 株式会社上野製薬応用研究所 下 剤
ES2051862T3 (es) 1987-10-02 1994-07-01 Ueno Seiyaku Oyo Kenkyujo Kk Un metodo para producir un medicamento que tiene un efecto catartico.
JP2579193B2 (ja) 1988-07-19 1997-02-05 小野薬品工業株式会社 １６，１６−ジフルオロ−１５−オキソ−１５−デオキシｐｇｅ誘導体
CA2030344C (en) 1989-11-22 2000-04-18 Ryuji Ueno Treatment of pulmonary dysfunction with 15-keto-prostaglandin compounds
JPH0791192B2 (ja) * 1989-11-22 1995-10-04 株式会社上野製薬応用研究所 ガス交換機能不全処置剤
TW249226B (es) 1990-04-04 1995-06-11 Aderk Ueno Kk
DE69130586T2 (de) * 1990-05-01 1999-06-17 R Tech Ueno Ltd Behandlung von Pankreaskrankheit mit 15-keto-Prostaglandin E-Derivaten
CA2150287C (en) * 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
US6015828A (en) * 1996-05-31 2000-01-18 Cuppoletti; John Chemical modification of chloride channels as a treatment for cystic fibrosis and other diseases
KR19990036322A (ko) 1996-06-10 1999-05-25 류지 우에노 엔도텔린길항제
WO1999018968A1 (fr) * 1997-10-13 1999-04-22 R-Tech Ueno, Ltd. Inhibiteur de l'hypertension portale
ES2310013T3 (es) 1997-11-28 2008-12-16 Sucampo Ag Uso de compuestos de 15-ceto-prostaglandina e como antagonistas de endotelina.
CA2333038C (en) * 1998-05-25 2008-12-02 Taisho Pharmaceutical Co., Ltd. Sleep-inducing preparation
JP2003527430A (ja) 2000-03-24 2003-09-16 スカンポ・アクチェンゲゼルシャフト １５−ケトプロスタグランジンまたはその誘導体を含むアポトーシス抑制剤
ATE433754T1 (de) 2000-04-06 2009-07-15 Sucampo Ag Gallensäurefördernde zusammensetzung für lebertransplantation welche ein 15-keto prostaglandin enthält
TWI302100B (en) 2001-05-02 2008-10-21 Sucampo Ag Composition for treating drug-induced constipation
FR2829293B1 (fr) * 2001-08-31 2003-11-14 Centre Nat Rech Scient Memoire moleculaire et son procede de fabrication

Also Published As

Publication number Publication date
US7253295B2 (en) 2007-08-07
JP2005504836A (ja) 2005-02-17
TWI298256B (en) 2008-07-01
CA2458471C (en) 2012-07-31
CA2458471A1 (en) 2003-04-17
EP1420794B1 (en) 2017-12-27
JP2011102313A (ja) 2011-05-26
EP1420794A1 (en) 2004-05-26
AU2002330747B2 (en) 2007-07-19
JP5568021B2 (ja) 2014-08-06
BR0212233A (pt) 2004-10-05
JP4786866B2 (ja) 2011-10-05
US20060122411A1 (en) 2006-06-08
US20030130352A1 (en) 2003-07-10
WO2003030912A1 (en) 2003-04-17
NZ531503A (en) 2006-01-27
US7064148B2 (en) 2006-06-20
AR036391A1 (es) 2004-09-08

Similar Documents

Publication Publication Date Title
MXPA04002006A (es) Analogos de prostagladina como abridor del canal de cloruro.
HK1070369A1 (en) Sodium channel blockers
HK1081199A1 (en) Process and intermediates for the preparation of (1r,2s,5s)-6,6-dimethyl-3- azabicyclo [3,1,0] hexane-2-carboxylates or salts thereof
IN2012DN00606A (es)
TW200626559A (en) Anilino-pyrimidine analogs
HK1068609A1 (en) Sodium channel blockers
MXPA03011329A (es) Antiinfecciosos novedosos.
AU2003215174A1 (en) "crystalline aluminosilicate zeolitic composition: uzm-9"
MXPA03007450A (es) Metodos para producir dioxido de titanio practicamente libre de anatasa, con adicion de haluro de silicio.
WO2004106296A3 (en) Trisubstituted heteroaromatic compounds as calcium sensing receptor modulators
MXPA04000210A (es) Conjugados quelantes mejorados.
HK1047088A1 (zh) 鉀通道開放劑
MXPA05013751A (es) Procedimiento e intermediarios para la preparacion de 3-(amino)-3-ciclobutilmetil-2-hidroxi-propionamida o sus sales.
ATE373642T1 (de) Kalium kanalaktivatoren
MXPA03004986A (es) Proceso para preparar polimeros de emulsion con alta pureza.
RS8604A (en) Process for the production of beraprost and its salts
IL195385A0 (en) A process for preparing arylamine derivatives
MXPA04001248A (es) Reduccion del crecimiento del vello.
GB2342352B (en) Pure cis-tramadol hydrochloride production
GB2358137B (en) Compound
MXPA03006969A (es) Abridores de canal de potasio.
MXPA03007071A (es) Aminaldionas como abridores del canal de potasio.
GEP20063936B (en) New anhydrous crystalline forms of gabapentin
MXPA04005788A (es) Proceso para preparacion de derivados de [1,4,5]-oxadiazepina.
TW200624422A (en) Process for production of 2-chloro-4-nitroimidazole

Legal Events

Date Code Title Description
FG Grant or registration